KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.
The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.
The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.
About Schering-Plough Corporation
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch ering-plough.com.
CONTACT: Media Contact: Lee A. Davies, +1-908-298-7127; or InvestorContact: Alex Kelly, +1-908-298-7436
Web site: http://www.schering-plough.com/
Ticker Symbol: (:SGP)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company